Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Abbott's Xinlay To Face Advisory Committee Review Sept. 13; Celgene's Revlimid On Agenda

This article was originally published in The Pink Sheet Daily

Executive Summary

GlaxoSmithKline's Arranon (nelarabine) for acute lymphoblastic leukemia will also be part of the Sept. 13-14 meeting of FDA's Oncologic Drugs Advisory Committee.

You may also be interested in...

Genentech/OSI's Tarceva Given Sept. 13 Cmte. Review For Pancreatic Cancer

Supplemental NDA is based on a single Phase III trial of Tarceva plus Lilly's Gemzar vs. Gemzar and placebo.

Abbott Atrasentan Meta-Analysis Of Failed Trials Is "Centerpiece" Of NDA

The company plans to complete the NDA filing for Xinlay in metastatic prostate cancer by year-end, which is ahead of the timetable predicted after a pivotal trial failed to reach statistical significance. A Phase III trial in a second indication is likely to finish in 2005.

Spectrum’s Iso-Vorin Could Clear FDA For Osteosarcoma By First Quarter

The Irvine, Calif., firm also plans sNDAs for a colorectal cancer claim and an oral formulation of the leucovorin relative.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts